Elicitation of Strong Immune Responses by a DNA Vaccine Expressing a Secreted Form of Hepatitis C Virus Envelope Protein E2 in Murine and Porcine Animal Models

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Nov 30

PMID 17131474

Citations 8

Authors

Yi-Ping Li

Hye-Na Kang

Lorne-A Babiuk

Qiang Liu

Affiliations

Soon will be listed here.

Abstract

Aim: To characterize the immunogenicity of a hepatitis C virus (HCV) E2 DNA vaccine alone or with a protein vaccine boost in murine and porcine animal models.

Methods: A DNA vaccine expressing a secreted form of HCV E2 protein was constructed and used to vaccinate mice and piglets with or without boosting with a recombinant E2 protein vaccine formulated with CpG ODN and 10% Emulsigen. The immunogenicity of HCV E2 vaccines was analyzed by ELISA for antibody responses, MTT assay for lymphocyte proliferation, ELISPOT for the number of interferon-gamma secreting cells, and cytotoxic T lymphocyte assays.

Results: Intradermal injection of E2 DNA vaccine induced strong Th1-like immune responses in mice. In piglets, E2 DNA vaccine elicited moderate and more balanced immune responses. A DNA vaccine prime and protein boost vaccination strategy induced significantly higher E2-specific antibody levels and shifted the immune response towards Th2-like ones in piglets.

Conclusion: A DNA vaccine expressing a secreted form of HCV E2 protein elicited E2-specific immune responses in mice and piglets. Recombinant E2 protein vaccination following DNA immunization significantly increased the antibody response in piglets. These HCV E2 vaccines may represent promising hepatitis C vaccine candidates for further investigations.

Citing Articles

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.

Bouazzaoui A, Abdellatif A Vaccine X. 2024; 19:100500.

PMID: 38873639 PMC: 11170481. DOI: 10.1016/j.jvacx.2024.100500.

Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs.

Co-Rives I, Chen A, Moore A Vaccines (Basel). 2023; 11(2).

PMID: 36851328 PMC: 9962282. DOI: 10.3390/vaccines11020450.

Hepatitis C virus DNA vaccines: a systematic review.

Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Yaghoobi M Virol J. 2021; 18(1):248.

PMID: 34903252 PMC: 8667529. DOI: 10.1186/s12985-021-01716-8.

Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants.

Bouazzaoui A, Abdellatif A, Al-Allaf F, Bogari N, Al-Dehlawi S, Qari S Pharmaceutics. 2021; 13(2).

PMID: 33499096 PMC: 7911318. DOI: 10.3390/pharmaceutics13020140.

Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs.

Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan A Gene Ther. 2015; 23(1):26-37.

PMID: 26262584 DOI: 10.1038/gt.2015.86.

References

Hoofnagle J . Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S21-9. DOI: 10.1053/jhep.2002.36227. View

Ioannou X, Gomis S, Karvonen B, Hecker R, Babiuk L, van Drunen Littel-van den Hurk S . CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine. 2002; 21(1-2):127-37. DOI: 10.1016/s0264-410x(02)00378-x. View

Pancholi P, Perkus M, Tricoche N, Liu Q, Prince A . DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic.... J Virol. 2002; 77(1):382-90. PMC: 140575. DOI: 10.1128/jvi.77.1.382-390.2003. View

Goffard A, Dubuisson J . Glycosylation of hepatitis C virus envelope proteins. Biochimie. 2003; 85(3-4):295-301. DOI: 10.1016/s0300-9084(03)00004-x. View

Liu Q, Zaiss A, Colarusso P, Patel K, Haljan G, Wickham T . The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther. 2003; 14(7):627-43. DOI: 10.1089/104303403321618146. View

Lemieux P . Technological advances to increase immunogenicity of DNA vaccines. Expert Rev Vaccines. 2003; 1(1):85-93. DOI: 10.1586/14760584.1.1.85. View

Doria-Rose N, Haigwood N . DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods. 2003; 31(3):207-16. DOI: 10.1016/s1046-2023(03)00135-x. View

Youn J, Park S, Cho J, Sung Y . Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. J Virol. 2003; 77(21):11596-602. PMC: 229347. DOI: 10.1128/jvi.77.21.11596-11602.2003. View

Park S, Yang S, Lee C, Youn J, Chang J, Sung Y . Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine. 2003; 21(31):4555-64. DOI: 10.1016/s0264-410x(03)00499-7. View

10.

Rollier C, Depla E, Drexhage J, Verschoor E, Verstrepen B, Fatmi A . Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol. 2003; 78(1):187-96. PMC: 303385. DOI: 10.1128/jvi.78.1.187-196.2004. View

11.

Ha S, Kim D, Baek K, Yun Y, Sung Y . IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol. 2003; 172(1):525-31. DOI: 10.4049/jimmunol.172.1.525. View

12.

Penin F, Dubuisson J, Rey F, Moradpour D, Pawlotsky J . Structural biology of hepatitis C virus. Hepatology. 2004; 39(1):5-19. DOI: 10.1002/hep.20032. View

13.

Manoj S, Babiuk L, van Drunen Littel-van den Hurk S . Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci. 2004; 41(1):1-39. DOI: 10.1080/10408360490269251. View

14.

Leung L, Srivastava I, Kan E, Legg H, Sun Y, Greer C . Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS. 2004; 18(7):991-1001. DOI: 10.1097/00002030-200404300-00006. View

15.

Rothschild M . Porcine genomics delivers new tools and results: this little piggy did more than just go to market. Genet Res. 2004; 83(1):1-6. DOI: 10.1017/s0016672303006621. View

16.

Puig M, Major M, Mihalik K, Feinstone S . Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004; 22(8):991-1000. DOI: 10.1016/j.vaccine.2003.09.010. View

17.

Yu H, Babiuk L, van Drunen Littel-van den Hurk S . Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol. 2004; 85(Pt 6):1533-1543. DOI: 10.1099/vir.0.79821-0. View

18.

Zhu L, Liu J, Ye Y, Xie Y, Kong Y, Li G . A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol. 2004; 10(17):2488-92. PMC: 4572147. DOI: 10.3748/wjg.v10.i17.2488. View

19.

Abraham J, Himoudi N, Kien F, Berland J, Codran A, Bartosch B . Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine. 2004; 22(29-30):3917-28. DOI: 10.1016/j.vaccine.2004.04.005. View

20.

Simmonds P . Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004; 85(Pt 11):3173-3188. DOI: 10.1099/vir.0.80401-0. View